Notice2022-01517
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
January 26, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. to achieve expeditious commercialization of results of federally-funded research and development.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 17 (Wednesday, January 26, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 17 (Wednesday, January 26, 2022)]
[Notices]
[Pages 4037-4038]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-01517]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. to achieve
expeditious commercialization of results of federally-funded research
and development.
FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained
by emailing the indicated licensing contact at the National Heart,
Lung, and Blood, Office of Technology Transfer and Development Office
of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda,
MD 20892-2479; Michael Shmilovich; <a href="/cdn-cgi/l/email-protection#63100b0e0a0f0c150e230d0a0b4d040c15"><span class="__cf_email__" data-cfemail="d0a3b8bdb9bcbfa6bd90beb9b8feb7bfa6">[email protected]</span></a>; telephone: 301-
435-5019. A signed Confidential Disclosure Agreement may be required to
receive any unpublished information.
SUPPLEMENTARY INFORMATION: Technology description follows.
Sulfur and Selenium Containing Cannabinoid Receptor Modulating
Compounds
Available for licensing and commercial development are sulfur- and
selenium-containing pyrazole molecules for potentially treating
metabolic disorders, psychiatric disorders, neurological disorders,
pain disorders,
[[Page 4038]]
gastrointestinal disorders, cancers, inflammation-related disorders,
substance abuse associated pathologies, and other conditions using the
same. The filed provisional patent application includes extensive
descriptions of the exemplary molecules and their various constituents.
Therapeutic targets of said molecules include but are not limited to
the cannabinoids 1 receptor, the cannabinoid 2 receptor, GPR55, GPR18,
or GPR119. The rights pursued claim compounds, pharmaceutical
compositions, and methods of use.
Potential Commercial Applications:
<bullet> Pharmaceuticals
<bullet> Cancer therapy
<bullet> Inflammatory and autoimmune disease
Development Stage:
<bullet> Early stage
Inventors: Malliga R. Iyer, Ph.D. (NIAAA).
Intellectual Property: HHS Reference No. E-190-2021-0; U.S.
Provisional Patent Application No. 63/265,225 filed December 10, 2021.
Licensing Contact: Michael Shmilovich; 301-435-5019;
<a href="/cdn-cgi/l/email-protection#ea878389828b8f86c49982878386859c838982aa848382c48d859c"><span class="__cf_email__" data-cfemail="34595d575c5551581a475c595d585b425d575c745a5d5c1a535b42">[email protected]</span></a>.
Dated: January 20, 2022.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood
Institute, Office of Technology Transfer and Development.
[FR Doc. 2022-01517 Filed 1-25-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on January 26, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.